Attenuation of a rocuronium‐induced neuromuscular block in patients receiving prednisolone

Abstract

Prednisolone treatment in patients with inflammatory bowel disease is associated with a delayed onset and a shorter duration of action of rocuronium. The presence of an inflammatory bowel disease did not influence the neuromuscular block.

Residual neuromuscular block in type II diabetes mellitus after rocuronium

“…Our control group had a DURTOF 90 consistent with that reported by other studies, considering mean age, anaesthetic procedure and rocuronium dose used. [11][12][13][14][15][16][17][18][19][20] Our results are also in agreement with Saitoh in the significantly longer times to reappearance of T1, T2, T3 and T4 in diabetic patients. 4-6 Saitoh also found a significantly lower TOF ratio at 120 min in the diabetic group.…”

Different magnitude of resistance to non-depolarizing muscle relaxants in dexamethasone-treated rat diaphragm associated with altered acetylcholine receptor expression

“…Soltész et al (2008Soltész et al ( , 2009 found a shorter duration of atracurium (ATR)-induced neuromuscular block in patients receiving long-term prednisolone medication and later confirmed that this was also valid for rocuronium (ROC). Parr et al (1991) observed that patients on long-term betamethasone treatment required 75% more vecuronium (VEC).…”

High dose methylprednisolone counteracts the negative effects of rocuronium on diaphragm function

“…Values are shown as means ± SD and are expressed as percentage of CMV. *p \ 0.05 ROC versus others and # p \ 0.05 CMV versus ROC-MP patients with chronic inflammatory bowel disease [31]. In the present study, the use of NMBAs during mechanical ventilation resulted in a reduction of diaphragm force, while the combination of NMBAs together with a single dose of corticosteroids did not.…”